Menu Close

GlaxoSmithKline target adopts ‘poison pill’ – Philadelphia Inquirer


New York Times

GlaxoSmithKline target adopts 'poison pill'
Philadelphia Inquirer
By David Sell Human Genome Sciences Inc. filed a plan with regulators Thursday to try to block GlaxoSmithKline PLC's $2.6 billion takeover offer for the Maryland-based pharmaceutical company. The shareholder-rights plan — a corporate tactic often
Glaxo undeterred by Human Genome 'poison pill'Boston.com


Human Genome adopts 'poison pill' measureBusinessWeek

all 211 news articles »

This site uses Akismet to reduce spam. Learn how your comment data is processed.

RSS
Follow by Email
LinkedIn
Share